Research Analysts Set Expectations for COYA FY2024 Earnings

Coya Therapeutics, Inc. (NASDAQ:COYA) – Research analysts at HC Wainwright increased their FY2024 EPS estimates for Coya Therapeutics in a report released on Monday, November 11th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($1.13) per share for the year, up from their previous estimate of ($1.38). HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.27) per share. HC Wainwright also issued estimates for Coya Therapeutics’ Q4 2024 earnings at ($0.32) EPS, Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.50) EPS, Q4 2025 earnings at ($0.52) EPS and FY2025 earnings at ($1.68) EPS.

Separately, Chardan Capital reaffirmed a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a research note on Thursday, November 7th.

Coya Therapeutics Trading Down 0.1 %

COYA stock opened at $7.24 on Thursday. The company’s 50 day moving average is $7.10 and its 200 day moving average is $7.02. The stock has a market cap of $120.98 million, a price-to-earnings ratio of -11.14 and a beta of 0.46. Coya Therapeutics has a 1-year low of $4.75 and a 1-year high of $10.69.

Coya Therapeutics (NASDAQ:COYA) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.15.

Insider Activity

In other Coya Therapeutics news, CEO Arun Swaminathan purchased 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was bought at an average price of $7.34 per share, with a total value of $36,700.00. Following the completion of the purchase, the chief executive officer now directly owns 5,000 shares of the company’s stock, valued at $36,700. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 12.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Gilbert & Cook Inc. bought a new position in shares of Coya Therapeutics in the second quarter worth approximately $61,000. Renaissance Technologies LLC purchased a new position in shares of Coya Therapeutics in the 2nd quarter worth $101,000. GHP Investment Advisors Inc. purchased a new stake in Coya Therapeutics during the third quarter valued at $169,000. Finally, Vanguard Group Inc. boosted its position in Coya Therapeutics by 772.3% in the first quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after purchasing an additional 750,338 shares during the last quarter. Institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.